Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade B 6.14 -0.16% -0.01
ARDX closed down 0.16 percent on Friday, November 15, 2019, on 46 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ARDX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
NR7 Range Contraction -0.16%
Upper Bollinger Band Walk Strength -0.16%
Inside Day Range Contraction -0.16%
Wide Bands Range Expansion -0.16%
Overbought Stochastic Strength -0.16%
Up 3 Days in a Row Strength -0.16%
Up 4 Days in a Row Strength -0.16%
Up 5 Days in a Row Strength -0.16%

Older signals for ARDX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Biotechnology Biopharmaceutical Chronic Kidney Disease Astrazeneca End Stage Renal Disease Metabolic Diseases Rockwell Medical Södertälje Municipality Hyperphosphatemia
Is ARDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.78
52 Week Low 1.6
Average Volume 818,762
200-Day Moving Average 3.4693
50-Day Moving Average 5.0919
20-Day Moving Average 5.385
10-Day Moving Average 5.756
Average True Range 0.3243
ADX 43.38
+DI 27.48
-DI 7.3469
Chandelier Exit (Long, 3 ATRs ) 5.2471
Chandelier Exit (Short, 3 ATRs ) 5.3329
Upper Bollinger Band 6.2983
Lower Bollinger Band 4.4717
Percent B (%b) 0.91
BandWidth 33.920149
MACD Line 0.3698
MACD Signal Line 0.2814
MACD Histogram 0.0884
Fundamentals Value
Market Cap 291.32 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -2.52
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.44
Resistance 3 (R3) 6.43 6.33 6.39
Resistance 2 (R2) 6.33 6.25 6.33 6.37
Resistance 1 (R1) 6.23 6.20 6.18 6.24 6.36
Pivot Point 6.13 6.13 6.10 6.13 6.13
Support 1 (S1) 6.03 6.05 5.98 6.04 5.92
Support 2 (S2) 5.93 6.00 5.93 5.91
Support 3 (S3) 5.83 5.93 5.89
Support 4 (S4) 5.84